NCT07246421Recruiting
Glucagon Resistance in Patients With MASLD and T2DM
Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD). The main questions it aims to answer are: 1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD? 2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue? Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups. Participants will attend 2 short visits and 1 full-day visit, including: * Body scan (DXA) to check fat and bone composition * MRI to measure liver fat. * Blood tests. * Ultrasound to check liver stiffness and scarring. * Fat biopsies * 8-hour hormone (including glucagon) and tracer infusion * PET-CT scans
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 29 Jan 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- University of Aarhus
- NCT number
- NCT07246421
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 29 Jan 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Blood donation within the last 3 months prior to the study day
- Previous acute myocardial infarction (AMI)
Other illness
- Current or previous malignant disease
- Clinical symptoms of heart failure
- Current or previous malignant disease
- Known ongoing systemic disease, except for dyslipidaemia and hypertension
Lab values
- Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol/mol)
- Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions:
- Participants treated with statins may be included following a 2-week washout period prior to the experimental study day.
- Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only.
- Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.
Other
- Alcohol abuse (\>10 units per week for both sexes) or other substance abuse
- Smoking
- Participation in studies involving radioactive isotopes within the past 3 months
- Pregnancy
- C-peptide \< 200 pmol/L
Who the study is looking for
- BMI \> 26 kg/m²
- confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment
- steatosis FF% \> 5,6% on MR spectroscopy for MAFLD group
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.